10-Q: Alumis Reports Q2 2025 Results, Boosted by ACELYRIN Merger

Alumis Inc. reported a net income of $59.3 million for Q2 2025, driven by a significant gain from the ACELYRIN Merger, while advancing its lead product candidates envu and A-005 in clinical trials.

Summary

• Alumis Inc. reported a net income of $59.3 million for the three months ended June 30, 2025, a significant improvement from a net loss of $56.5 million in the same period last year.
• For the six months ended June 30, 2025, the company reported a net loss of $39.6 million, a reduction from a net loss of $106.4 million in the prior year period.
• Total revenue for the six months ended June 30, 2025, was $20.1 million, primarily from a $17.4 million license revenue and $2.7 million collaboration revenue from the Kaken Pharmaceutical Co., Ltd. agreement.
• Research and development expenses increased by 124% to $108.8 million for the three months ended June 30, 2025, and by 127% to $205.4 million for the six months ended June 30, 2025, driven by clinical trial progression and the ACELYRIN Merger.
• General and administrative expenses surged by 355% to $34.5 million for the three months ended June 30, 2025, and by 330% to $56.7 million for the six months ended June 30, 2025, largely due to ACELYRIN Merger transaction costs and increased headcount.
• The company recorded a gain on bargain purchase of $187.9 million in connection with the ACELYRIN Merger, which closed on May 21, 2025, acquiring net assets with a fair value of $426.0 million for a consideration of $238.1 million.
• Cash, cash equivalents, and marketable securities totaled $486.3 million as of June 30, 2025, up from $288.3 million as of December 31, 2024.
• The company's accumulated deficit as of June 30, 2025, was $698.2 million.
• The Phase 3 ONWARD clinical program for envudeucitinib (envu) in plaque psoriasis has been initiated, with topline results expected early in the first quarter of 2026.
• Topline results for the Phase 2 clinical trial of envu in systemic lupus erythematosus (SLE) are expected in the third quarter of 2026.
• The company acquired lonigutamab, a monoclonal antibody for Thyroid Eye Disease (TED), through the ACELYRIN Merger and is evaluating its development program.
• The Phase 2a clinical trial of envu in non-infectious uveitis was discontinued in June 2024 due to efficacy results not meeting the clinical threshold for success.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant net income driven by the ACELYRIN Merger's bargain purchase gain and the initiation of Phase 3 trials for envu. The Kaken collaboration also adds a new revenue stream. However, this is tempered by continued substantial operating losses, rapidly increasing R&D and G&A expenses, and the inherent high risks of clinical-stage biopharmaceutical development, including the discontinuation of one envu trial and ongoing litigation.

Positives

• Achieved a net income of $59.3 million for the three months ended June 30, 2025, primarily due to a significant gain on bargain purchase from the ACELYRIN Merger.
• Successfully completed the ACELYRIN Merger, strengthening the balance sheet and cash position by acquiring $49.7 million in cash, cash equivalents, and restricted cash, and $333.4 million in marketable securities.
• Secured a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for envu in dermatology indications in Japan, including an upfront payment of $20.0 million and future development cost reimbursements, milestones, and royalties.
• Advanced envu into Phase 3 clinical trials for plaque psoriasis, with topline results anticipated early in Q1 2026, indicating significant progress in its lead product candidate.
• Progressed envu into a Phase 2 clinical trial for systemic lupus erythematosus, with topline results expected in Q3 2026, expanding its potential indications.
• Initiated the Phase 1 program for A-005, a CNS-penetrant TYK2 inhibitor, demonstrating pipeline expansion into neuroinflammatory and neurodegenerative diseases.
• Increased total cash, cash equivalents, and marketable securities to $486.3 million as of June 30, 2025, providing liquidity for at least the next 12 months.

Negatives

• Continued to incur significant operating losses, with a loss from operations of $140.5 million for the three months ended June 30, 2025, and $242.1 million for the six months ended June 30, 2025.
• Accumulated deficit reached $698.2 million as of June 30, 2025, reflecting substantial historical losses.
• Research and development expenses significantly increased by $60.2 million (124%) for the three months and $114.9 million (127%) for the six months ended June 30, 2025, indicating high burn rate for clinical programs.
• General and administrative expenses rose sharply by $26.9 million (355%) for the three months and $43.5 million (330%) for the six months ended June 30, 2025, largely due to ACELYRIN Merger transaction costs and integration expenses.
• Discontinued the Phase 2a clinical trial of envu in non-infectious uveitis in June 2024 due to efficacy results not meeting the clinical threshold for success, representing a setback for that indication.
• Incurred substantial integration costs and expenses related to the ACELYRIN Merger, which are difficult to estimate accurately and could be greater or incurred over a longer period than expected.

Risks

• The company has a limited operating history and no products approved for commercial sale, having incurred substantial losses since inception and anticipating increasing losses for the foreseeable future.
• Substantial additional financing will be required to achieve goals, and failure to obtain capital on acceptable terms could delay, limit, reduce, or terminate product development or commercialization efforts.
• Preclinical and clinical development is a lengthy, expensive, and uncertain process, with earlier trial results not necessarily predictive of future outcomes, potentially leading to additional costs or delays.
• Clinical trials may reveal serious adverse events (SAEs) and significant adverse events (AEs) not previously observed, which could delay or prevent regulatory approval or market acceptance of product candidates.
• The company faces intense competition from large and specialty pharmaceutical and biotechnology companies, many of which have greater resources and approved therapies.
• Various risks are related to the acquisition of ACELYRIN, including challenges in attracting/retaining key personnel, maintaining relationships, diverting management attention, and the possibility that anticipated benefits may not be fully realized.
• The business is highly dependent on the success of envu, and there is no guarantee it will successfully complete development, receive regulatory approval, or be commercialized.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, and failure to obtain approval would substantially harm the business.
• Dependence on the services of the management team and other clinical and scientific personnel, with inability to retain or recruit new personnel potentially harming the business.
• Inability to obtain and maintain sufficient intellectual property protection for product candidates, or if the scope of protection is not broad enough, could allow competitors to commercialize similar products.
• International trade policies, including tariffs, sanctions, and trade barriers, particularly affecting suppliers outside the U.S. (India, Taiwan, EU, South Korea), may adversely affect business operations and increase costs.
• Reliance on third-party manufacturers and suppliers for product candidates, with risks of loss, non-compliance, or insufficient quantities, which could materially and adversely affect the business.
• Significant risk of product liability inherent in the development, testing, manufacturing, and marketing of new treatments, potentially leading to claims, investigations, or recalls.
• Exposure to significant uninsured liabilities, as insurance policies may not cover all business risks or provide sufficient coverage.
• Strategic transactions, including acquisitions like ACELYRIN, could impact liquidity, increase expenses, dilute stockholders, and distract management.
• Ability to use net operating loss carryforwards and other tax attributes to offset taxable income or taxes may be limited due to ownership changes (e.g., Section 382/383 of the Internal Revenue Code).
• Recent and future changes to tax laws (e.g., OBBBA, IRA) could materially adversely affect the company.
• Information technology systems, or those of third parties, are vulnerable to security breaches, loss of data, or other disruptions, leading to material adverse consequences.
• Operations are predominantly concentrated in California, exposing the company to risks from natural disasters like wildfires and earthquakes.
• Projections regarding market opportunities for product candidates may not be accurate, and the actual market may be smaller than estimated.
• Cash and cash equivalents are exposed to the risk of banking institution failures, potentially impairing access to funds.
• Public opinion and scrutiny of immunology treatments may negatively impact public perception, clinical trial enrollment, or business plans.
• Future impairment of In-Process Research and Development (IPR&D) intangible assets related to the ACELYRIN Merger may negatively affect results of operations and financial position.
• Actual financial positions and results of operations may differ materially from unaudited pro forma financial information.
• Involvement in third-party claims of intellectual property infringement, which may prevent or delay product discovery and development efforts.
• Inability to obtain or maintain necessary rights to product candidates through acquisitions and in-licenses, potentially leading to abandonment of development programs.
• Conflicts with current or future licensors or collaborators could delay or prevent the development or commercialization of product candidates.
• The company's stock price is likely to remain volatile, influenced by various factors including clinical trial results, competitor announcements, and macroeconomic conditions.

Future Outlook

The company expects to continue incurring significant and increasing expenses and substantial losses for the foreseeable future as it advances product candidates through clinical trials, seeks regulatory approvals, expands its product pipeline, and integrates the acquired ACELYRIN business. Profitability is dependent on successful development, approval, and commercialization of product candidates, and the achievement of sufficient revenue to support its cost structure. The company believes its existing cash, cash equivalents, and marketable securities of $486.3 million as of June 30, 2025, will be sufficient to meet operating and capital requirements for at least 12 months. Significant additional capital will be needed to fund ongoing research and development and future operations, potentially through equity, debt financings, strategic alliances, or licensing arrangements.

Management Comments

• Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
• We are continuing to evaluate the development program for lonigutamab and its potential differentiation in a capital efficient manner.
• We expect to continue to incur substantial losses for the foreseeable future, and our ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of any product candidates we may develop, and on the achievement of sufficient revenue to support our cost structure.
• We anticipate that our expenses will increase significantly in connection with our ongoing activities, particularly as we continue to progress the development of our product candidates in multiple clinical trials in parallel and commit substantial capital resources to the integration and development activities related to the acquired ACELYRIN business.

Industry Context

The biopharmaceutical industry is highly competitive, with significant investments in developing treatments for immunological indications. Alumis focuses on Tyrosine Kinase 2 (TYK2) inhibitors for autoimmune disorders like plaque psoriasis and systemic lupus erythematosus, and a CNS-penetrant TYK2 inhibitor for neuroinflammatory diseases. The acquisition of lonigutamab expands its portfolio into Thyroid Eye Disease (TED). The industry faces challenges including lengthy and expensive development processes, intense competition from established players with greater resources, and evolving regulatory landscapes, including new EU regulations and U.S. healthcare reform measures like the Inflation Reduction Act impacting drug pricing. Macroeconomic conditions, such as rising interest rates and inflation, also affect operational costs and financing availability.

Comparison to Industry Standards

• The company's lead product candidate, envu, is a second-generation TYK2 inhibitor, competing with other TYK2 inhibitors like deucravacitinib (marketed as Sotyktu), which is approved for plaque psoriasis. The filing notes that deucravacitinib has shown adverse events such as hypersensitivity reactions, infections, malignancy, and rhabdomyolysis, and its label includes a warning concerning JAK-related AEs like cardiovascular and thrombotic events. Alumis's envu has observed AEs including headaches, upper respiratory tract infections, nasopharyngitis, rash, and nausea, with some serious adverse events (peritonsillar abscess, non-small cell lung cancer, renal cell carcinoma, arthritis) in its open-label extension trial, which are being evaluated against the known side effects of TYK2 inhibition.
• For lonigutamab, acquired through the ACELYRIN Merger, the company is evaluating its potential differentiation from the sole currently-approved therapy in the United States for Thyroid Eye Disease (TED). The filing highlights that lonigutamab's potential to improve on the safety and side-effect profile of the existing therapy is unproven, noting observed adverse events in its Phase 2 trial including headache, tinnitus, and injection site reactions. This suggests a direct comparison to the existing TED treatment's safety and efficacy profile will be critical for market disruption.
• The company's reliance on third-party Contract Manufacturing Organizations (CMOs) and Clinical Research Organizations (CROs) is a common industry practice, but the filing emphasizes the risks associated with this reliance, including limited control over timing and quality, and the need for compliance with cGMPs and GCPs, which are standard regulatory requirements across the biopharmaceutical industry.

Management Changes

Legal Proceedings

• A federal securities class action lawsuit, Boukadoum v. Acelyrin, Inc. et al., was commenced on November 15, 2023, in the United States District Court for the Central District of California, naming ACELYRIN and its then-current and former executive officers and directors as defendants.
• The amended complaint, filed on March 26, 2024, alleges violations of the Exchange Act and Securities Act by misleading investors about the Phase 2b trial of izokibep in hidradenitis suppurativa, specifically regarding the primary endpoint of HiSCR75 at week 16 not meeting statistical significance.
• The lawsuit seeks damages and an award of reasonable costs and expenses, including attorneys' fees and expert fees.
• Defendants filed a motion to dismiss the amended complaint on May 3, 2024, which remains pending.
• The company has not accrued for any potential liability relating to this lawsuit, as it does not consider any payment to be probable or reasonably estimable at this early stage.

Related Party Transactions

• The company has a services agreement with Foresite Labs, LLC, an affiliate of Foresite Capital Management (a stockholder of the company), which provides services to assist in exploring specified immunology genetic targets.
• For the three and six months ended June 30, 2025, the company recognized $0.3 million and $0.5 million, respectively, as research and development expenses under this service agreement.

Stakeholder Impact

• **Shareholders:** The ACELYRIN Merger resulted in a significant gain on bargain purchase, contributing to net income for the quarter, which could positively impact investor sentiment. However, the company's continued operating losses and need for future capital raises could lead to further dilution of ownership interest. The stock price remains volatile due to various factors, including clinical trial results and market conditions.
• **Employees:** The ACELYRIN Merger led to increased headcount in both research and development and general and administrative functions. However, it also resulted in severance costs for terminated ACELYRIN employees and accelerated vesting of equity awards, indicating some workforce restructuring and potential impact on employee morale and retention.
• **Patients:** The advancement of envu into Phase 3 trials for plaque psoriasis and Phase 2 for SLE, along with the acquisition of lonigutamab for TED, offers potential new therapeutic options for patients with autoimmune and neuroinflammatory disorders. The discontinuation of the envu uveitis trial means patients in that indication will not benefit from that specific program.
• **Suppliers/CMOs/CROs:** The company's increased R&D expenses reflect higher engagement with CROs and CMOs for clinical trials and manufacturing, indicating continued business for these third-party partners. However, the company's reliance on limited source suppliers and the absence of long-term supply contracts with CMOs pose risks to supply chain stability and costs for these partners.
• **Creditors:** The company's increased cash and marketable securities position provides a stronger liquidity profile, which is favorable for creditors. However, the ongoing operating losses and the stated need for significant additional capital in the future highlight continued financial risk.

Next Steps

• Report topline results for the Phase 3 ONWARD clinical program of envu in plaque psoriasis early in the first quarter of 2026.
• Report topline results for the Phase 2 clinical trial of envu in systemic lupus erythematosus (SLE) in the third quarter of 2026.
• Continue to evaluate the development program for lonigutamab and its potential differentiation in a capital efficient manner.
• Monitor expenses and potentially raise additional capital through public/private equity, debt financings, strategic alliances, and licensing arrangements.
• Continue to progress the development of product candidates in multiple clinical trials in parallel.
• Continue committing substantial capital resources to the integration and development activities related to the acquired ACELYRIN business.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and disclosures.

Key Dates

Recommendation

While the reported net income for the quarter is a positive signal, it is primarily driven by a one-time gain from the ACELYRIN Merger rather than sustained operational profitability. The company continues to incur significant operating losses and has a substantial accumulated deficit, indicating a high burn rate. The advancement of lead product candidates into Phase 3 and Phase 2 trials is promising, but biopharmaceutical development is inherently risky, with high failure rates and long timelines. The discontinuation of the uveitis trial for envu underscores these risks. The company's need for significant additional capital in the future suggests potential further dilution. Given the mix of a one-time financial boost and ongoing operational challenges coupled with significant pipeline risks, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, future financing activities, and the company's ability to manage its increasing expenses and integrate the acquired business effectively.

Keywords

Biopharmaceutical, Immunology, Clinical Stage, TYK2 Inhibitor, Plaque Psoriasis, Systemic Lupus Erythematosus, Thyroid Eye Disease, Drug Development, SEC Filing, 10-Q, Merger, Clinical Trials, Biotech